STOP T1D — Screen TO Prevent Type 1 Diabetes
Released On
June 2026
Expires On
June 2028
Media Type
Internet
Completion Time
3.5 hrs
Specialty
Acute Care, Anesthesiology, Critical Care, Diabetes, Education, Emergency Medicine, Endocrinology, Gastroenterology, Hospitalist, Pediatrics, Pharmacy, Primary Care, Rheumatology
Topic(s)
Autoimmnunity, Diabetes, Pediatrics, Screening
Providers/Grant Support
This program is jointly provided by the Postgraduate Institute for Medicine (PIM) and the Barbara Davis Center for Diabetes, University of Colorado, Anschutz Medical Campus. This program is supported in part by a grant from Sanofi US.
Credit Available
- Physicians — maximum of 3.5 AMA PRA Category 1 Credits™
- Nurses — 3.5 Nursing Contact Hours
- Pharmacist — 3.5 contact hours (0.35 CEU)
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of physicians, nurses, pharmacists and other advanced practice providers who have interest in screening for and prevention of autoimmune diseases including type 1 diabetes.
Program Overview
This online enduring program is a comprehensive educational program for health care providers (HCPs) in the United States interested in type 1 diabetes (T1D) screening and monitoring programs. This activity aims to raise awareness among HCPs and communities about the critical importance of early detection and the severe consequences of delayed diagnosis of type 1 diabetes. In addition, it will educate and empower HCPs and healthcare organizations with the knowledge, competence, and tools necessary for effective screening, age-specific monitoring practices, and timely diagnosis.
Learning Objectives
Upon completion of the activity, HCPs will have improved ability to:
- Explain the significance of early detection of Type 1 Diabetes (T1D).
- Identify appropriate populations and screening methods for T1D.
- Apply monitoring protocols for individuals with positive autoantibodies.
- Demonstrate effective communication strategies when counseling patients with T1D and their families.
- Recognize the psychosocial impacts of T1D screening results.
- Discuss treatment options for T1D, including immunomodulatory therapies such as teplizumab..
- Collaborate effectively across interdisciplinary care teams to support T1D screening and management.
Faculty
Program Chairs
Marian Rewers MD, PhD
Professor of Pediatrics & Medicine
Richard S. Abrams Endowed Chair
Executive Director, Barbara Davis Center for Diabetes
Aurora, CO
Brigitte Frohnert MD, PhD
Associate Professor of Pediatrics
Barbara Davis Center for Diabetes
University of Colorado
Anschutz Medical Campus
Aurora, CO
Faculty
*ALL* faculty from: Barbara Davis Center for Diabetes, University of Colorado, Anschutz Medical Campus, Aurora, CO
Kimberly Bautista, MPH, Research Scientist
Hali Broncucia, MA, Senior Research Scientist
Cristy Geno, MPH, PhD, Assistant Professor of Pediatrics*
*At time of content development
Patricia Gesualdo, RN, MSPH, Senior Research Scientist
Holly O’Donnell, PhD, Assistant Professor of Pediatrics
Arleta Rewers, MD, PhD, Professor, Pediatrics-Emergency Medicine
Kimber Simmons, MD, MPH, Associate Professor of Pediatrics
Andrea Steck, MD, Professor of Pediatrics
Kathleen Waugh, MS, Senior Research Scientist
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the Barbara Davis Center for Diabetes, University of Colorado, Anschutz Medical Campus. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Credit Designation Statement
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.5 contact hours.
Continuing Pharmacy Education
The Postgraduate Institute for Medicine designates this continuing education activity for 3.5 contact hours of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-26-472-H01-P)
Type of Activity: Knowledge
Disclosures of Conflicts of Interest
Disclosure Policy Statement
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Barbara Davis Center planners have nothing to disclose.
Disclosure of Relevant Financial Relationships
All other faculty have nothing to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity.
To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be available for the participant to download.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Contact Information
For CME questions, please contact [email protected]